Mario Martin, B.; Cadavid Restrepo, A.; Mayfield, H.; Then Paulino, C.; De St Aubin, M.; Duke, W.; Jarolim, P.; Zielinski Gutiérrez, E.; Skewes Ramm, R.; Dumas, D.; Garnier, S.; Etienne, M.C.; Peña, F.; Abdalla, G.; Lopez, B.; de la Cruz, L.; Henríquez, B.; Baldwin, M.; Sartorius, B.; Kucharski, A.; Nilles, E.J.; Lau, C.L. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response. Trop. Med. Infect. Dis.2023, 8, 493.
Mario Martin, B.; Cadavid Restrepo, A.; Mayfield, H.; Then Paulino, C.; De St Aubin, M.; Duke, W.; Jarolim, P.; Zielinski Gutiérrez, E.; Skewes Ramm, R.; Dumas, D.; Garnier, S.; Etienne, M.C.; Peña, F.; Abdalla, G.; Lopez, B.; de la Cruz, L.; Henríquez, B.; Baldwin, M.; Sartorius, B.; Kucharski, A.; Nilles, E.J.; Lau, C.L. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response. Trop. Med. Infect. Dis. 2023, 8, 493.
Mario Martin, B.; Cadavid Restrepo, A.; Mayfield, H.; Then Paulino, C.; De St Aubin, M.; Duke, W.; Jarolim, P.; Zielinski Gutiérrez, E.; Skewes Ramm, R.; Dumas, D.; Garnier, S.; Etienne, M.C.; Peña, F.; Abdalla, G.; Lopez, B.; de la Cruz, L.; Henríquez, B.; Baldwin, M.; Sartorius, B.; Kucharski, A.; Nilles, E.J.; Lau, C.L. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response. Trop. Med. Infect. Dis.2023, 8, 493.
Mario Martin, B.; Cadavid Restrepo, A.; Mayfield, H.; Then Paulino, C.; De St Aubin, M.; Duke, W.; Jarolim, P.; Zielinski Gutiérrez, E.; Skewes Ramm, R.; Dumas, D.; Garnier, S.; Etienne, M.C.; Peña, F.; Abdalla, G.; Lopez, B.; de la Cruz, L.; Henríquez, B.; Baldwin, M.; Sartorius, B.; Kucharski, A.; Nilles, E.J.; Lau, C.L. Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response. Trop. Med. Infect. Dis. 2023, 8, 493.
Abstract
Incidence of COVID-19 has been associated with sociodemographic factors. We investigated variations in SARS-CoV-2 seroprevalence at sub-national levels in the Dominican Republic and assessed potential factors influencing variation in regional-level seroprevalence. Data were collected in a three-stage cross-sectional national serosurvey from June to October 2021. Seroprevalence of antibodies against the SARS-CoV-2 spike protein (anti-S) was estimated and adjusted for selection probability, age, and sex. Multilevel logistic regression was used to estimate the effect of covariates on seropositivity for anti-S and correlates of 80% protection (PT80) against symptomatic infection for ancestral and Delta strains. A total of 6,683 participants from 134 clusters in all 10 regions were enrolled. Anti-S, PT80 for ancestral and Delta strains odds ratio varied across regions, Enriquillo presented significant higher odds for all outcomes compared with Yuma. Compared to unvaccinated, receiving ≥2doses of COVID-19 vaccine was associated with a significantly higher odds of anti-S positivity (OR 85.94, [10.95-674.33]), and PT80 for ancestral (OR 4.78, [2.15-10.62]) and Delta strains (OR 3.08, [1.57-9.65]) nationally, and also for each region. Our results can help inform regional-level public health response, such as strategies to increase vaccination coverage in areas with low population immunity against currently circulating strains.
Keywords
SARS-CoV-2; seroprevalence; vaccine; spatial distribution
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.